Cimerli™ (ranibizumab-eqrn)
for Macular Degeneration

Cimerli (ranibizumab-eqrn) is a biosimilar to Lucentis used to treat macular degeneration, macular edema, and myopic choroidal neovascularization. It is an anti-angiogenic ophthalmic medication and VEGF inhibitor that works by preventing the growth of abnormal blood vessels under the retina, helping to preserve vision.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Macular Degeneration